Liver manifestations in a cohort of 39 patients with congenital disorders of glycosylation: pin-pointing the characteristics of liver injury and proposing recommendations for follow-up

Rodrigo Tzovenos Starosta1,2,3*, Suzanne Boyer2, Shawn Tahata4, Kimiyo Raymond5, Hee Eun Lee5, Lynne A. Wolfe6, Christina Lam7,8, Andrew C. Edmondson9, Ida Vanessa Doederlein Schwartz1,10 and Eva Morava2,5,11

Abstract

Background: The congenital disorders of glycosylation (CDG) are a heterogeneous group of rare metabolic diseases with multi-system involvement. The liver phenotype of CDG varies not only according to the specific disorder, but also from patient to patient. In this study, we sought to identify common patterns of liver injury among patients with a broad spectrum of CDG, and to provide recommendations for follow-up in clinical practice.

Methods: Patients were enrolled in the Frontiers in Congenital Disorders of Glycosylation natural history study. We analyzed clinical history, molecular genetics, serum markers of liver injury, liver ultrasonography and transient elastography, liver histopathology (when available), and clinical scores of 39 patients with 16 different CDG types (PMM2-CDG, n = 19), with a median age of 7 years (range: 10 months to 65 years). For patients with disorders which are treatable by specific interventions, we have added a description of liver parameters on treatment.

Results: Our principal findings are (1) there is a clear pattern in the evolution of the hepatocellular injury markers alanine aminotransferase and aspartate aminotransferase according to age, especially in PMM2-CDG patients but also in other CDG-I, and that the cholangiocellular injury marker gamma-glutamyltransferase is not elevated in most patients, pointing to an exclusive hepatocellular origin of injury; (2) there is a dissociation between liver ultrasound and transient elastography regarding signs of liver fibrosis; (3) histopathological findings in liver tissue of PMM2-CDG patients include cytoplasmic glycogen deposits; and (4) most CDG types show more than one type of liver injury.

Conclusions: Based on these findings, we recommend that all CDG patients have regular systematic, comprehensive screening for liver disease, including physical examination (for hepatomegaly and signs of liver failure), laboratory tests (serum alanine aminotransferase and aspartate aminotransferase), liver ultrasound (for steatosis and liver tumors), and liver elastography (for fibrosis).

Keywords: CDG, Liver injury, Phosphomannomutase-2, Liver fibrosis, Cirrhosis, Phenotyping, Glycosylation
Introduction
The congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic diseases, mostly autosomal recessive, that affect the complex process of building, remodeling, and transferring glycans to proteins and lipids. There are approximately 130 known CDG to date [1]. The current classification divides protein glycosylation according to which of the two main types of glycan attachment to proteins is affected [2]: N-linked or O-linked glycosylation. N-linked CDG are further subdivided based on whether the enzymatic defect impacts the assembly and transfer of primary glycan chains in the endoplasmic reticulum (CDG-I) or the maturation of glycan chains in the Golgi apparatus (CDG-II). Because of the ubiquity of glycosylation in human physiology [3], CDG tend to be multisystem diseases, affecting different organs and tissues in a heterogeneous way [4]. One of the most commonly affected organs in many CDG is the liver, due to its central role in protein secretion [4]; however, there is limited study of the liver phenotype of CDG beyond PMM2-CDG [5].

PMM2-CDG (MIM: #212065) is the most common CDG, with more than a thousand patients reported so far [6]. Most PMM2-CDG patients have mild liver dysfunction with increased serum aminotransferases, especially during the first 5 years of life, when all-cause lethality is also higher [5]; however, a proportion of patients develops steatosis, fibrosis/cirrhosis, and may die from the complications of liver failure [5]. Other CDG have more specific hepatic phenotypic characteristics. For instance, CCDC115-CDG (MIM: #616828) and MPI-CDG (MIM: #602579) have especially severe liver disease [7]. CCDC115-CDG presents with a Wilson disease-like phenotype with hepatosplenomegaly, increased serum aminotransferases, neonatal jaundice, early cirrhosis, and increased liver copper concentration [8–10]; other CDG involved with Golgi membrane trafficking such as TMEM199-CDG can also present with similar Wilsonian features [11, 12]. MPI-CDG tends to present with severe liver dysfunction and rapidly progressive (sometimes congenital) fibrosis [7, 13], although asymptomatic adults have been reported [14, 15]. Other CDG, such as ALG8-CDG (MIM: #603147), can present with severe liver disease with cirrhosis and complications of portal hypertension, with high lethality [7].

The hepatic phenotype in CDG is complex and understanding the manifestations and the type of liver injury to be expected in a patient is critical for appropriate management. In this study, we prospectively evaluate a large cohort of patients with different CDG types to systematically explore the hepatic phenotype of these disorders, seeking to identify common patterns of liver injury and to derive recommendations for clinical practice.

Methods
Subjects
Patients with a molecularly confirmed diagnosis of CDG and biochemical confirmation of the specific defect were recruited to the Frontiers of Congenital Disorders of Glycosylation (FCDGC) natural history study or to the CDG Nutritional Intervention study at Mayo Clinic. Retrospective and prospective data collection was part of the enrollment process, as the patients have been previously followed-up by standard of care.

Data extraction
Blood tests were considered to be elevated when the results were above the reference levels on two or more occasions; in subjects having only one test, it was considered elevated if above the reference level in this measurement. The number of subjects with a given manifestation is represented over the number of subjects with an available result for such manifestation, not over the total number of subjects.

The following variables for the composite categorical parameters on extra-hepatic phenotype were used, being considered as positive when at least one of the variables in each parameter was abnormal: hematological abnormalities (hemoglobin, white blood cell count, platelet count); coagulation abnormalities (prothrombin time, activated partial thromboplastin time, factor XI activity, antithrombin III activity, clinically significant bleeding or thrombosis); dyslipidemia (low-density lipoprotein, high-density lipoprotein, total cholesterol, triglycerides); hypothyroidism (thyroid-stimulating hormone); glucose homeostasis (blood glucose, documented hypoglycemia); seizures (history of seizures, diagnosis of epilepsy). These categories were chosen based on the predominant extra-hepatic features of most CDG and on the availability of data.

The Nijmegen Pediatric CDG Rating Score (NPCRS) was performed in every patient in the study by the same investigator (EM). The NPCRS is a clinical tool developed as a means of quantifying clinical severity of patients with CDG in a global and comprehensive way, and is validated for all age groups [16].

Statistical analysis
Categorical variables were compared using Fisher’s exact test with a significance level of \( p < 0.05 \). Q–Q plots were used to determine approximate parametricity. Parametric continuous variables were compared in an exploratory analysis between groups using Student’s \( t \)-test with a significance level of \( p < 0.05 \). A logistic
regression was used to identify correlations of continuous variables with categorical outcomes, with a significance level of \( p < 0.05 \).

**Results**

**Subjects**

Thirty-nine patients were included in the study. Median age was 7 years (range: 10 months to 65 years), and 66.7% (26/39) were male (Table 1). The most common diagnosis was PMM2-CDG (n = 19); followed by ALG12-CDG

| Patient | Age (Y) | Sex | CDG | Genotype | Protein change | ALT range | AST range | AlkP range |
|---------|---------|-----|-----|----------|---------------|-----------|-----------|------------|
| 1       | 1       | M   | PMM2-CDG | c.44G>C; c.422G>A | p.Gly15Ala; p.Arg141His | 15–145 | 10–147 | 172–301 |
| 2       | 1       | M   | PMM2-CDG | c.357C>A; c.422G>A | p.Phe119Leu; p.Arg141His | 103–571 | 93–829 | 172–304 |
| 3       | 2       | M   | PMM2-CDG | c.357C>A; c.422G>A | p.Phe119Leu; p.Arg141His | 53–1595 | 54–1222 | 224–462 |
| 4       | 3       | M   | PMM2-CDG | c.422G>A; c.691G>A | p.Arg141His; p.Val231Met | 48–66 | 54–57 | 173–182 |
| 5       | 5       | M   | PMM2-CDG | c.422G>A; c.710T>C | p.Arg141His; p.Phe183Ser | 34–41 | 23 | 186 |
| 6       | 6       | F   | PMM2-CDG | c.338C>T; c.710C>G | p.Phe113Leu; p.Phe234Arg | 8–745 | 13–678 | 17–283 |
| 7       | 6       | M   | PMM2-CDG | c.357C>A; c.422G>A | p.Phe119Leu; p.Arg141His | 25–1366 | 25–1986 | 115–1083 |
| 8       | 6       | F   | PMM2-CDG | c.415G>A; c.422G>A | p.Glu39Lys; p.Arg141His | 19–31 | 31–48 | 157–250 |
| 9       | 6       | M   | PMM2-CDG | c.338C>T; c.422G>A | p.Pro113Leu; p.Arg141His | 32–2524 | 26–4789 | 60–292 |
| 10      | 6      | F   | PMM2-CDG | c.563A>G; c.691G>A | p.Asp188Gly; p.Val231Met | 38–556 | 31–457 | 228–299 |
| 11      | 7       | M   | PMM2-CDG | c.205C>T; c.422G>A | p.Pro69Ser; p.Asp148Asn | 28 | 42 | 225–242 |
| 12      | 9       | F   | PMM2-CDG | c.205C>T; c.422G>A | p.Arg141His | 15–20 | 29–34 | 139–149 |
| 13      | 11      | M   | PMM2-CDG | c.98A>C; c.140C>T | p.Arg141His; p.Cys241Ser | 17–18 | 25–26 | 154–172 |
| 14      | 12      | M   | PMM2-CDG | c.707T>C; c.422G>A | p.Phe119Leu; p.Arg141His | 25–1366 | 25–1986 | 115–1083 |
| 15      | 12      | M   | PMM2-CDG | c.422G>A; c.647A>T | p.Asp188Gly; p.Val231Met | 38–556 | 31–457 | 228–299 |
| 16      | 13      | M   | PMM2-CDG | c.422G>A; c.647A>T | p.Arg141His; p.Arg141His | 44–68 | 46–58 | 187–240 |

Table 1: Patient characteristics and markers of liver injury

*Patients 20–21; 24–25 are siblings

Y years old, ALT alanine aminotransferase, AST aspartate aminotransferase, AlkP alkaline phosphatase, M male, F female. Age displayed is the current age. Normal ranges: ALT < 42 IU/L; AST < 41 IU/L; AlkP < 300 IU/L.
Clinical findings

Clinical descriptions were available for all patients. Six patients had hepatomegaly on physical exam (patients 2, 6, 8, 11, 23, and 34). Three patients had neonatal jaundice requiring phototherapy (patients 10, 12, and 26), but no patient had jaundice outside of the neonatal period. One patient had ascites (patient 6); no patient had other stigmata of liver disease (e.g., caput medusae, gynecomastia, or palmar erythema) on physical exam, although one patient (patient 7) had unexplained pruritus. Patient 6 underwent liver transplantation at 4 years of age because of liver failure (hyperammonemia, recurrent ascites).

Molecular findings

All patients had genetically confirmed CDG genotypes. The most common genetic variant found in PMM2 was c.422G > A (p.Arg141His), comprising 14/38 (36.8%) of alleles reported (Table 1). The only homozygous PMM2 variant found was c.357C > A (p.Phe119Leu). Two different PMM2 variants were found to arise in the same nucleotide position: c.710C > G (p.Thr234Arg) and c.710C > T (p.Thr234Met).

Liver biopsy

Histopathological reports for liver tissue were available for three patients: two patients underwent liver biopsy and one had an explanted liver. The liver explanted from patient 6 (PMM2-CDG) showed micronodular cirrhosis on gross and microscopic examination (Fig. 2); there was mild macrovesicular steatosis and mild-to-moderate biliary ductular proliferation, as well as multiple foci of hepatocellular glycogen storage in the cytoplasm; iron staining was negative. Patient 7 (PMM2-CDG) had a liver biopsy at 3 years of age that showed broad, irregular bridging fibrosis with minimal mixed (macrovesicular and microvesicular) steatosis and increased hepatocellular glycogen, with no signs of biliary changes, iron overload, or hepatocellular regeneration. Patient 34 (CCDC115-CDG) had a liver biopsy at 2 years of age that showed cirrhosis with extensive portal and periportal bridging fibrosis, microvesicular steatosis, positive glycogen staining with fine hepatocellular cytoplasm vacuolization in a mosaic pattern, with no signs of biliary changes or iron overload. All glycogen deposits were confirmed by positivity on periodic acid Schiff (PAS) staining, with attenuation after diastase treatment.

Treatment effects

Eight patients underwent specific monosaccharide supplementation therapy for CDG in this study. Patient 26 with PGM1-CDG started treatment with oral galactose.
0.5 g/kg/day at age 2 years, with a planned increase to 1 g/kg/day after 6 weeks of the escalating dose. ALT and AST were elevated before treatment, with a rapid decrease (3 weeks) after introduction of treatment. (Fig. 3a). Patient 27 with PGM1-CDG started treatment with oral galactose 0.5 g/kg/day at age 27 years, with a significant decrease in AST and ALT within 6 months after introduction of treatment (Fig. 3b). Patient 28 with SLC35A2-CDG started treatment with oral galactose 1.5 g/kg/day at age 6 months. AST and GGT were elevated before treatment, which both normalized on treatment within 4 months, and additionally, significant
improvement was observed in other clinical features such as seizure control and motor skills. Patient 29 with SLC35A2-CDG started treatment with oral galactose 1.5 g/kg/day at age 10 years. There was a mild transient elevation in ALT and AST levels after initiation of treatment (Fig. 3c). Although transaminases normalized after the initial increase, no significant improvement was observed in clinical features during the first 4 months of therapy, as described elsewhere [18]. Patient 33 with MPI-CDG has been on treatment with oral mannose 1 g/kg/day divided in 6 doses at age 4 years for 2 years. High aminotransferase values were observed during the whole

| Patient | CDG     | Age at ultrasound (Y) | Ultrasound findings                                      | Transient elastography result |
|---------|---------|------------------------|----------------------------------------------------------|-------------------------------|
| 1       | PMM2    | 1                      | Coarse liver parenchyma                                   | F0 (3.8 kPa)                  |
| 2       | PMM2    | 1                      | Coarse liver parenchyma                                   | –                             |
| 3       | PMM2    | 1                      | Steatosis*                                                | –                             |
| 4       | PMM2    | 4                      | Coarse liver parenchyma                                   | –                             |
| 5       | PMM2    | 5                      | Coarse liver parenchyma                                   | –                             |
| 6       | PMM2    | 6                      | Central intrahepatic bile duct dilation, otherwise normal | F2 (8.4 kPa)                  |
| 7       | PMM2    | 6                      | Normal                                                   | –                             |
| 8       | PMM2    | 6                      | Normal                                                   | –                             |
| 9       | PMM2    | 5                      | Hemangioma, otherwise normal                             | F1 (7.3 kPa)                  |
| 10      | PMM2    | 6                      | “Starry sky” parenchyma                                   | –                             |
| 11      | PMM2    | 10                     | Normal                                                   | –                             |
| 12      | PMM2    | 10                     | Steatosis                                                | –                             |
| 13      | PMM2    | 28                     | Coarse liver parenchyma                                   | –                             |
| 14      | ALG13   | 1                      | Geographic steatosis                                      | –                             |
| 15      | ALG13   | 4                      | Multiple well-circumscribed echogenic lesions             | –                             |
| 16      | DHDDS   | 63                     | Normal                                                   | –                             |
| 17      | PGM1    | 2                      | Increased echogenicity                                    | –                             |
| 18      | SLC35A2 | 4 days                 | Normal                                                   | –                             |
| 19      | ALG8    | 6                      | Steatosis                                                | –                             |
| 20      | MPI     | –                      | –                                                        | F2 (8.0 kPa)                  |
| 21      | CCDC115 | 2                      | Mildly increased echogenicity                             | –                             |
| 22      | SLC39A8 | 2                      | Coarse liver parenchyma                                   | –                             |
| 23      | TMEM165 | 12                     | Normal                                                   | –                             |
| 24      | VMA21   | 34                     | Normal                                                   | –                             |

* Resolved subsequently

Fig. 2 a liver, hematoxylin and eosin, 20 ×. Cirrhotic liver tissue with extensive bridging and enlarged portal tract. There is focal glycogen deposition in the cytoplasm of hepatocytes of a nodule (black arrow). b Liver, hematoxylin and eosin, 200 ×. Hepatocellular nodule with cytoplasmic glycogen deposition (black arrow). c Liver, hematoxylin and eosin, 200 ×. Hepatocellular nodule with discrete macrovesicular steatosis
period of 2 years of treatment and the patient needed additional nutritional intervention with a complex carbohydrate diet. Patient 36 with SLC35C1-CDG started treatment with oral fucose 2 g/day at age 10 years, with an increase to 4 g after 6 months of therapy and 8 g/day at age 11 years. There was no elevation of ALT, AST, or AlkP before or during treatment (Fig. 3d), although clinical parameters such as tendency to infections were improved. Patient 37 with SLC39A8-CDG started treatments with oral galactose 1 g/kg/day at age 2 years and escalating doses of manganese from 5 mg/day to 65 mg/day during a period of 6 months. No significant change was observed in ALT and AST levels after introduction of treatment; however, the patient had significant clinical improvement with respect to seizure control and motor development over the first 6 months of therapy. Patient 38 with TMEM165-CDG started treatment with oral galactose 1.5 g/kg/day at age 5 years. No pre-treatment laboratory results are available. High aminotransferase values were observed during treatment.

Nijmegen Pediatric CDG rating scale (NPCRS)
A NPCRS [16] score was available for 38 patients. The total median was 21, ranging from 4 to 40. NPCRS medians (range) by CDG subgroup were: PMM2-CDG = 24 (15–40); non-PMM2 type I CDG = 17.5 (4–27); for type II CDG = 25 (4–35). A Q-Q plot determined the distribution of NPCRS values to be approximately normal. There was no difference in the total NPCRS values between patients with elevated ALT and patients with normal ALT (p = 0.215). A significant difference was found in the NPCRS scores between patients with elevated and normal AST values, with patients with elevated AST measurements having higher NPCRS values (respectively, 23.46±8.04 vs 15.60±6.83, p = 0.009). A binary logistic regression between having high AST values and
the tree sections of the NPCRS showed that this significant association is due to the first section ("current function") only, with $p = 0.045$, $r^2 = 0.353$. When analyzing only CDG-I patients, we identified that increases in both ALT and AST are associated with higher NPCRS scores (ALT: $23.52 \pm 7.57$ vs $17.25 \pm 6.52$, $p = 0.028$; AST: $23.15 \pm 7.03$ vs $16.00 \pm 7.12$, $p = 0.018$); a binary logistic regression showed that this significant association is due to the second section for ALT ($p = 0.022$, $r^2 = 0.412$), but to no specific section for AST (lowest $p = 0.094$). There was no association with a higher rate of elevated ALT or AST and a diagnosis of PMM2-CDG versus another type I CDG (ALT, $p = 0.148$; AST, $p = 0.422$). On a subgroup analysis (grouping patients according to specific CDG), however, we did not find any significant difference in total NPCRS scores or sections.

Patients with PMM2-CDG and a diagnosis of coarse liver parenchyma on ultrasound had a non-significantly higher NPCRS than PMM2-CDG patients who did not have this diagnosis ($29.00 \pm 8.28$ vs $23.37 \pm 5.15$, $p = 0.173$).

**Extra-hepatic associations**

Prevalence of extra-hepatic manifestations of CDG is displayed in Table 3. A significant association was found in the co-distribution of high ALT levels and abnormal coagulation parameters (85% of patients with high ALT levels had coagulation abnormalities vs 22.7% of patients with coagulation abnormalities with normal ALT, $p = 0.002$) and hypothyroidism, as defined by elevated TSH measurements (all patients with hypothyroidism had high ALT values vs 41.3% of patients without hypothyroidism having high ALT values, $p = 0.004$). No association was found in the co-distribution of high ALT levels and abnormal hematological parameters, dyslipidemia, glucose homeostasis, or seizures. For high AST values, a significant association was found for coagulation parameters (73.1% of patients with high AST levels had coagulation abnormalities vs 13.6% of patients who had normal AST values, $p = 0.026$) and seizures (65.5% of patients with high AST levels had seizures vs 13.6% of patients who had normal AST values, $p = 0.037$).

### Discussion

The liver is one of the main sites of N-glycosylation in the body [19] and is responsible for the attachment of glycans to most secreted proteins. CDG affect the liver in a number of ways. In this retrospective/prospective study we have described a cohort of patients with 16 different CDG and confirmed [7] that serum aminotransferases, which are common, reliable markers of hepatocellular injury, are mostly elevated during the first 5 years of life in most types of CDG but improve significantly after

**Table 3  Prevalence of extra-hepatic manifestations in CDG patients**

| CDG       | Hematological abnormalities | Coagulation abnormalities | Dyslipidemia | Hypothyroidism | Glucose homeostasis | Seizures |
|-----------|-----------------------------|---------------------------|--------------|----------------|---------------------|----------|
| PMM2      | 3/15                        | 12/15                     | 4/11         | 6/15           | 8/13                | 8/16     |
| ALG6      | N/A                         | 1/1                       | 0/1          | 0/1            | 0/1                 | 1/1      |
| ALG8      | 0/1                         | 1/1                       | N/A          | 0/1            | 0/1                 | 1/1      |
| ALG12     | N/A                         | 2/2                       | 0/2          | 0/2            | 0/2                 | 0/2      |
| ALG13     | 0/2                         | 0/2                       | 1/1          | 0/2            | 0/2                 | 2/2      |
| CCDC115   | 0/1                         | 0/1                       | 1/1          | N/A            | 0/1                 | 0/1      |
| DDOST     | 0/1                         | 0/1                       | 1/1          | 0/1            | 1/1                 | 0/1      |
| DHDDS     | 1/2                         | 2/2                       | 2/2          | 0/2            | 2/2                 | 1/2      |
| MPI       | 0/1                         | 1/1                       | N/A          | 1/1            | 1/1                 | 1/1      |
| PGM1      | 1/2                         | 2/2                       | 0/1          | 1/2            | 2/2                 | 0/2      |
| SLC10A7   | 0/1                         | 1/1                       | 1/1          | 0/1            | 0/1                 | 0/1      |
| SLC35A2   | 1/2                         | 0/2                       | 1/1          | 0/2            | 1/2                 | 2/2      |
| SLC35C1   | 0/1                         | N/A                       | N/A          | 0/1            | 0/1                 | 0/1      |
| SLC39A8   | 0/1                         | 0/1                       | N/A          | 0/1            | 0/1                 | 1/1      |
| TMEM165   | 0/1                         | 0/1                       | 1/1          | 0/1            | 0/1                 | 1/1      |
| VMA21     | 0/1                         | 0/1                       | 1/1          | 0/1            | 0/1                 | 0/1      |

Values are displayed as the number of patients with the manifestation divided by the number of patients for whom there was available data regarding the manifestation.
this age. Exceptions to this in our study were ALG8-CDG, CCDC115-CDG, MPI-CDG, PGM1-CDG, and TMEM165-CDG patients. In contrast to aminotransferases, we found that few patients had an elevation of the cholangiocyte injury marker GGT, and that most of such elevations were mild. Normal GGT in the setting of elevated aminotransferases had previously been reported in isolated cases of CDG [8, 13], but to the best of our knowledge this is the first time it has been reported systematically. This highlights the hepatocellular, rather than global, nature of liver damage in this group of disorders.

The most common finding on liver ultrasound was a coarse liver parenchyma, which is usually associated with fibrotic changes. However, we have observed a disparity between liver ultrasound and transient elastography, a fibrosis-directed measurement. Unfortunately, we only have data from a few patients on liver elastography, because elastography has not been considered as standard-of-care in pediatric patients with CDG, and these studies were performed prior to the study recruitment. Nonetheless, the disparity between elastography and liver ultrasound results indicates that both liver ultrasound and elastography should be used for follow-up in patients in CDG.

When analyzing the relationship between elevations of serum aminotransferases and extra-hepatic manifestations, we found that both elevated ALT and AST are associated with the presence of coagulation factor abnormalities. Since most coagulation factors are glycosylated in the liver, these changes mirror the degree of glycosylation abnormality. This highlights the necessity of screening for coagulopathy in patients with high aminotransferases in this population; however, it must be remembered that it is possible to find abnormal activity levels of coagulation factors and inhibitors with normal aminotransferase levels.

We had access to specimens of liver tissue from 3 patients. In the two PMM2-CDG patients, there were increased cytoplasmic glycogen deposits. In one of these patients this finding was in the context of liver cirrhosis and may be considered as a part of the cirrhotic phenotype [20]. The presence of scattered hepatocytes with foci of glycogenosis in the other may suggest a disturbance of hepatic glycogen breakdown which could stem from excessive mannose-6-phosphate being shunted to fructose-6-phosphate by mannose-phosphate isomerase [21] and feeding into glycolysis, which can inhibit glycogenolysis by ultimately increasing intracellular adenosine triphosphate. In the biopsy of the patient with CCDC115-CDG we could not observe any signs of cholestasis, foamy histiocytes, or necrotic lesions, as described [8, 9]. This highlights the heterogeneity of manifestations within a single type of CDG and depending on age.

We have observed different effects of short-term monosaccharide treatment according to the type of CDG. For PGM1-CDG, there was a rapid improvement in aminotransferase levels after introduction of galactose therapy, as expected [22–24]. For SLC35A2-CDG aminotransferases were mildly elevated before treatment in one patient, with improvement after galactose was initiated; and a mild transient elevation in aminotransferases in the other with normalization shortly thereafter. We did also notice improvement in neurological features (data not shown) as expected [18, 24, 25]. In MPI-CDG and TMEM165-CDG, mannose and galactose supplementation, respectively, do not always fully correct or prevent liver damage [13, 26, 27], and our observations match this expectation. SLC35C1-CDG affects primarily leukocytes and the central nervous system [28], and therapeutic goals with fucose supplementation involve restoration of immune function and improvement of neurological function [29]. SLC39A8-CDG affects primarily bone development and central nervous system function, without significant hepatic findings [30], in line with our findings.

Recently, Ferreira et al. proposed a categorization of metabolic liver disease according to the type of liver manifestation [31] including diseases with hepato-megaly, hepatocellular disease with elevation of aminotransferases or liver failure, cholestasis, steatosis, fibrosis, and liver tumors. Most CDG span more than one category (Tables 4, 5). This warrants the recommendation that every CDG patient be systematically evaluated for different types of liver disease with a combination of physical exam, laboratory testing, ultrasonography, and elastography.

**Conclusion**

In summary, in our retrospective/prospective dataset of CDG patients we confirm spontaneous improvement of hepatocellular injury markers AST and ALT in CDG-I but not in CDG-II. There was a dissociation between liver ultrasound and transient elastography results in several patients necessitating prospective liver elastography in CDG patients to survey for possible liver fibrosis. The cytoplasmic glycogen deposits found in liver biopsy specimens raise the hypothesis that a disturbance of glycogen metabolism may be present in PMM2-CDG, leading to a need of further investigation. Based on our findings, we recommend that all CDG patients have regular systematic, comprehensive screening for liver disease, including clinical, laboratory and imaging techniques that detect both steatosis and fibrosis.
Table 4  Distribution of liver manifestations per CDG in this study

| CDG     | Hepatomegaly | Hepatocellular disease | Cholestasis | Steatosis | Fibrosis | Liver tumor |
|---------|--------------|------------------------|-------------|-----------|----------|-------------|
| PMM2    | +            | +                      | +           | +         | +        | +           |
| ALG6    | −            | +                      | −           | N/A       | N/A      | −           |
| ALG8    | −            | +                      | −           | +         | −        | −           |
| ALG12   | −            | −                      | −           | N/A       | N/A      | −           |
| ALG13   | +            | +                      | −           | +         | −        | +           |
| CCDC115 | +            | +                      | −           | +         | +        | −           |
| DDOST   | −            | −                      | +           | N/A       | N/A      | −           |
| DHDDS   | −            | −                      | −           | −         | −        | −           |
| MPI     | −            | +                      | −           | N/A       | +        | −           |
| PGM1    | −            | +                      | −           | N/A       | N/A      | −           |
| SLC10A7 | −            | +                      | −           | N/A       | N/A      | −           |
| SLC35A2 | −            | +                      | −           | −         | −        | −           |
| SLC35C1 | −            | −                      | −           | N/A       | N/A      | −           |
| SLC39A8 | −            | −                      | −           | −         | −        | −           |
| TMEM165 | −            | +                      | −           | −         | −        | −           |
| VMA21   | −            | +                      | −           | −         | −        | −           |

Classification adapted from Ferreira et al. [31]. Hepatomegaly was defined as an enlarged liver on physical exam or ultrasonography. Hepatocellular disease was defined as elevated ALT or AST. Cholestasis was defined as jaundice, elevated bilirubin, or histopathological evidence of bile accumulation. Steatosis was defined as ultrasonographic or histopathological evidence of hepatocellular lipid accumulation. Fibrosis was defined as transient elastography score equal or greater than F1 or histopathological evidence of fibrosis. Liver tumor was defined as any imaging evidence of tumoral growth (neoplastic or non-neoplastic) in the liver. + denotes presence of the manifestation in the phenotype of at least one patient with the disorder; − denotes absence of the manifestation in all patients analyzed.

Table 5  Distribution of liver manifestations by CDG as reported in the literature

| CDG     | Hepatomegaly | Hepatocellular disease | Cholestasis | Steatosis | Fibrosis | Liver tumor | References |
|---------|--------------|------------------------|-------------|-----------|----------|-------------|------------|
| PMM2    | +            | +                      | +           | +         | +        | −           | [5–7]      |
| ALG6    | +            | +                      | +           | +         | +        | −           | [7, 32]    |
| ALG8    | +            | +                      | +           | +         | +        | −           | [7]        |
| ALG12   | −            | +                      | −           | −         | −        | −           | [33]       |
| ALG13   | +            | +                      | −           | −         | −        | −           | [34]       |
| CCDC115 | +            | +                      | +           | +         | +        | −           | [7]        |
| DDOST   | −            | +                      | −           | −         | −        | −           | [35]       |
| DHDDS   | +            | +                      | +           | −         | −        | −           | [36]       |
| MPI     | +            | +                      | −           | +         | +        | −           | [37]       |
| PGM1    | +            | +                      | −           | +         | +        | −           | [7]        |
| SLC10A7 | −            | −                      | −           | −         | −        | −           | [38, 39]   |
| SLC35A2 | −            | +                      | −           | −         | −        | −           | [7]        |
| SLC35C1 | −            | −                      | −           | −         | −        | −           | [7]        |
| SLC39A8 | −            | −                      | −           | −         | −        | −           | [7]        |
| TMEM165 | +            | +                      | −           | −         | −        | −           | [40]       |
| VMA21   | −            | +                      | +           | +         | −        | −           | [41]       |

Classification adapted from Ferreira et al. [31]. Hepatomegaly was defined as an enlarged liver on physical exam or ultrasonography. Hepatocellular disease was defined as elevated ALT or AST. Cholestasis was defined as jaundice, elevated bilirubin, or histopathological evidence of bile accumulation. Steatosis was defined as ultrasonographic or histopathological evidence of hepatocellular lipid accumulation. Fibrosis was defined as transient elastography score equal or greater than F1 or histopathological evidence of fibrosis. Liver tumor was defined as any imaging evidence of tumoral growth (neoplastic or non-neoplastic) in the liver. + denotes presence of the manifestation in the phenotype of at least one patient with the disorder; − denotes absence of the manifestation in all patients analyzed. The column “References” refer to the positive findings in each disorder.
Acknowledgements
Not applicable.

Authors’ contributions
RTS conceived and designed the study; extracted, analyzed and interpreted the data; wrote the primary manuscript; and submitted the final manuscript. SB, ST, LAW, CL, ACE analyzed and interpreted data; and provided critical revision of the manuscript with contribution of important intellectual content. KR and HEL extracted, analyzed and interpreted data; and provided critical revision of the manuscript with contribution of important intellectual content. IVDS conceived the study; analyzed and interpreted data; and provided critical revision of the manuscript with contribution of important intellectual content. EM conceived and designed the study; obtained bioethical authorization and grant funding; managed funding; analyzed and interpreted data; provided critical revision of the manuscript with contribution of important intellectual content and wrote intermediate versions of the manuscript; is the guarantor for this study. All authors read and approved the final manuscript.

Funding
This work was funded by the grant titled Frontiers in Congenital Disorders of Glycosylation (U1S4NS115198-01) from the National Institute of Neurological Diseases and Stroke (NINDS) and the Rare Disorders Consortium Disease Network (RDCRN). RTS was supported by the Coordenación de Apefriacoamiento de Pessoal de Nivel Superior – Programa Institucional de Internacionalização (CAPES/PRINT) #002-2019. Brazil. The funding bodies did not have any role in the study design or in the collection, analysis, and interpretation of data, or in writing the manuscript.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Mayo Clinic under protocols #18-007276 and #19-005187. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

Consent for publication
All subjects provided signed informed consent for publication, which are available upon request.

Availability of data and material
All data generated or analyzed during this study are included in this published article.

Competing interests
The authors declare that they have no competing interest.

Author details
1 Graduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil. 2 Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA. 3 Department of Pediatrics, Washington University in Saint Louis, St. Louis, MO, USA. 4 Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 5 Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 6 Undiagnosed Diseases Program, Common Fund, National Institutes of Health, Bethesda, MD, USA. 7 Division of Genetic Medicine, University of Washington, Seattle, WA, USA. 8 Center of Integrated Brain Research, Seattle Children’s Research Institute, Seattle, WA, USA. 9 Section of Biochemical Genetics, Division of Human Genetics, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 10 Service of Medical Genetics, Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre, RS, Brazil. 11 Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

Received: 14 September 2020   Accepted: 27 November 2020

References
1. Francisco R, Marques-da-Silva D, Brasil S, Pascoal C, Dos Reis FV, Morava E, Jaeken J. The challenge of CDG diagnosis. Mol Genet Metab. 2019;126(1):1–5.
2. Péanne R, de Lonlay P, Foulier F, Kornak U, Lefebre DJ, Morava E, Pérez B, Seta N, Thiel C, Van Schaftingen E, et al. Congenital disorders of glycosylation (CDG): Quo vadis? Eur J Med Genet. 2018;61(1):643–63.
3. Fisher P, Thomas-Dates J, Wood AJ, Unger D. The N-glycosylation processing potential of the mammalian Golgi apparatus. Front Cell Dev Biol. 2019;7:157.
4. Verheijen J, Tahta S, Koizctz T, Witters P, Morava E. Therapeutische approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update. Genet Med. 2020;22(2):268–79.
5. Witters P, Honzlik T, Bauchart E, Altassan R, Pasceau T, Brunet A, Vuil- laumier S, Seta N, Borgel D, Matthijs G, et al. Long-term follow-up in PMM2-CDG: are we ready to start treatment trials? Genet Med. 2021;23(1):1181–8.
6. Altassan R, Péanne R, Jaeken J, Barone R, Bidet M, Borgel D, Brasil S, Cassimman D, Cecehova A, Coman D, et al. International clinical guidelines for the management of phosphomannomutase 2 congenital disorders of glycosylation: diagnosis, treatment and follow up. J Inherit Metab Dis. 2019;42(1):5–28.
7. Marques-da-Silva D, Dos Reis Ferreira V, Monticelli M, Janeiro P, Videira P, Witters P, Jaeken J, Cassiman D. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J Inherit Metab Dis. 2017;40(2):195–207.
8. Girard M, Poujois A, Fabre M, Lalacalle F, Debray D, Rio M, Fenna-Le, Chofl S, Ruel C, Caússé E, et al. CCDC115-CDG: a new rare and misleading inherited cause of liver disease. Mol Genet Metab. 2018;124(3):228–35.
9. Jansen JC, Cirak S, van Scherpenzeel M, Timal S, Reunert J, Rust S, Pérez B, Vicogne D, Krawitz P, Wada Y, et al. CCDC115 deficiency causes a disorder of Golgi homeostasis with abnormal protein glycosylation. Am J Hum Genet. 2016;98(2):310–21.
10. Medrano C, Vega A, Navarrete R, Ecat MJ, Calvo R, Pascual SI, Ruiz-Pons M, Toledo L, García-Jiménez I, Arroyo L, et al. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain. Clin Genet. 2019;95(5):615–26.
11. Jansen JC, Timal S, van Scherpenzeel M, Michalakakis H, Vicogne D, Ashikov A, Maroutian M, Hoischen A, Huijben K, Steenbergen G, et al. TMEM199 deficiency is a disorder of Golgi homeostasis characterized by elevated aminotransferases, alkaline phosphatase, and cholesterol and abnormal glycosylation. Am J Hum Genet. 2016;98(2):322–30.
12. Vajro P, Zietlinska K, Ng BG, Macarana M, Bengtsson P, Poeta M, Mandato C, D’Acuto E, Freeze HH, Ellund EA. Three unreported cases of TMEM199-CDG; a rare genetic liver disease with abnormal glycosylation. Orphanet J Rare Dis. 2018;13(1).
13. Mention K, Lalacalle F, Valayanopoulos V, Romano S, Kuster A, Cretz M, Zaider H, Galmiche L, Jaubert F, de Keyzer Y, et al. Development of liver abnormalities in patients with congenital disorders of N-linked glycosylation (CDG): Quo vadis? Eur J Med Genet. 2018;7:157.
14. De la Morena-Barrio ME, Wypasek E, Gómez-Piñero A, Vicente J, Ensenauer R, de Baulny HO, Ounap K, Martinelli D, de Vries M, et al. Nijnegen paediatric CDG rating scale: a novel tool to assess disease progression. J Inherit Metab Dis. 2011;34(4):923–7.
15. Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94(5):515–34.
16. Achouitar S, Mohamed M, Gardeitchik T, Wortmann SB, Sykut-Cegielska J, Ensenauer R, de Baulny HO, Ounap K, Martinelli D, de Vries M, et al. Antithrombin deficiency. Haematologica. 2019;104(2):e79–82.
17. Ossendrijver P, Hoganson G, Scaglia F, Lewis AM, Mori M, et al. Clinical and biochemical progression. J Inherit Metab Dis. 2013;36(4):579–82.
18. Achen G, Huijben K, Steenbergen G, et al. Aspartate aminotransferase deficiency (MIM-CDG) initially mistaken for excessive alcohol consumption. Clin Chim Acta. 2014;431:15–8.
19. Zaidan H, Galmiche L, Jaubert F, de Keyzer Y, et al. Development of liver abnormalities in patients with congenital disorders of N-linked glycosylation (CDG): Quo vadis? Eur J Med Genet. 2018;13(1).
20. Ashikov A, Moraitou M, Hoischen A, Huijben K, Steenbergen G, et al. TMEM199 deficiency is a disorder of Golgi homeostasis characterized by elevated aminotransferases, alkaline phosphatase, and cholesterol and abnormal glycosylation. Am J Hum Genet. 2008;93(1):40–3.
21. Hamlender A, Jaeken J, Matthijs G, Egertsen G. Asymptomatic phosphomannose isomerase deficiency (MPI-CDG) initially mistaken for excessive alcohol consumption. Chin Clin Acta. 2014;431:15–8.
22. de la Morena-Barrio ME, Wypasek E, Ossendrijver P, Miñana A, Vicente J, Corral I, Undas A. MPI-CDG with transient hypoglycosylation and antithrombin deficiency. Haematologica. 2019;104(2):e79–82.
23. Achouitar S, Mohamed M, Gardeitchik T, Wortmann SB, Sykut-Cegielska J, Ensenauer R, de Baulny HO, Ounap K, Martinelli D, de Vries M, et al. Nijnegen paediatric CDG rating scale: a novel tool to assess disease progression. J Inherit Metab Dis. 2011;34(4):923–7.
24. Frulloni N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94(5):515–34.
25. Witters P, Tahata S, Barone R, Ounap K, Salvareno R, Gregorov S, Hognason G, Scaglia F, Lewis AM, Mori M, et al. Clinical and biochemical improvement with galactose supplementation in SLC3A2-CDG. Genet Med. 2020;22:1102–7.
19. Zhu J, Sun Z, Cheng K, Chen R, Ye M, Xu B, Sun D, Wang L, Liu J, Wang F, et al. Comprehensive mapping of protein N-glycosylation in human liver by combining hydrophilic interaction chromatography and hydrazide chemistry. J Proteome Res. 2014;13(3):1713–21.

20. Bannasch P, John U, Hacker H, Su Q, Hoffmann W, Pichlmayr R, Otto G. Focal hepatic glycogenosis. Int J Oncol. 1997;10(2):261–8.

21. Freeze HH. Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-ia patients. Biochim Biophys Acta. 2009;1792(9):835–40.

22. Wong SY, Gadomski T, van Scherpenzeel M, Kolk M, Bowling F, Sykut-Cegielska J, Koch D, et al. Oral D-galactose supplementation in PGM1-CDG. Genet Med. 2017;19(11):1226–35.

23. Radenkovic S, Bird MJ, Emmerzaal TL, Wong SY, Felgueira C, Stiers KM, Sabbagh L, Himmelreich N, Poschet G, Windmolders P, et al. The meta-analysis of the nutritional therapies in congenital disorders of glycosylation (CDG) type I. J Inherit Metab Dis. 2016;39(5):713–23.

24. Tsim S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, Paprocka J, Jamroz E, van Sponsten FJ, Körner C, et al. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet. 2012;21(19):4151–61.

25. Jones MA, Ng BG, Bhide S, Chin E, Rhodenizer D, He P, Losfeld ME, He M, Raymond K, Berry G, et al. DDOST mutations identified by whole-exome sequencing are implicated in congenital disorders of glycosylation. Am J Hum Genet. 2012;90(2):363–8.

26. Sabry S, Vulliumier-Barrot S, Mintet E, Fasseu M, Valayannopoulos V, Héron D, Dorison N, Mignot C, Seta N, Chantret I, et al. A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity. Orphanet J Rare Dis. 2016;11(1):84.

27. Cechevov A, Altassan R, Borger D, Bruneel A, Correa J, Giraud M, Haroche A, Kiec-Wilk B, Mohnike K, Pascaume T, et al. Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation. J Inherit Metab Dis. 2020;43:671–93.

28. Vals MA, Ashikov A, Ilves P, Loorits D, Zeng Q, Barone R, Huijben K, Sykut-Cegielska J, Døgro L, Elias AF, et al. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients. J Inherit Metab Dis. 2019;42(3):553–64.

29. Ng BG, Sosicka P, Agadi S, Almamuni M, Bacino CA, Barone R, Botto LD, Burton JE, Carlston C, Chung BH, et al. SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported individuals. Hum Mutat. 2019;40(7):908–25.

30. Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, Bammens R, Morelle W, Potelle S, Witters P, Wong S, Climer L, Lupashin V, Matthijs G, Dörre K, Olczak M, Wada Y, Sosicka P, Grüneberg M, Reunert J, Kurlemann G, Fiedler B, Biskup S, Hörtnagel K, et al. Galactose supplementation in patients with MPI-CDG rescues the glycosylation defects. J Clin Endocrinol Metab. 2017;102(4):1375–86.

31. Vals MA, Ashikov A, Ilves P, Loorits D, Zeng Q, Barone R, Huijben K, Sykut-Cegielska J, Døgro L, Elias AF, et al. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients. J Inherit Metab Dis. 2019;42(3):553–64.

32. Cannata Serio M, Graham LA, Ashikov A, Larsen LE, Raymond K, Barone R, Botto LD, Burton JE, Carlston C, Chung BH, et al. SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported individuals. Hum Mutat. 2019;40(7):908–25.

33. Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, Bammens R, Morelle W, Rosnoblet C, Legrand D, et al. TMEM165 deficiency causes a congenital disorder of glycosylation. Am J Hum Genet. 2012;91(1):15–26.

34. Cannata Serio M, Graham LA, Ashikov A, Larsen LE, Raymond K, Tsiakas K, Santer R, Grüneberg M, et al. SLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy. Hum Mol Genet. 2014;23(11):2880–7.

35. Tsim S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, Paprocka J, Jamroz E, van Sponsten FJ, Körner C, et al. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet. 2012;21(19):4151–61.

36. Jones MA, Ng BG, Bhide S, Chin E, Rhodenizer D, He P, Losfeld ME, He M, Raymond K, Berry G, et al. DDOST mutations identified by whole-exome sequencing are implicated in congenital disorders of glycosylation. Am J Hum Genet. 2012;90(2):363–8.

37. Sabry S, Vulliumier-Barrot S, Mintet E, Fasseu M, Valayannopoulos V, Héron D, Dorison N, Mignot C, Seta N, Chantret I, et al. A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity. Orphanet J Rare Dis. 2016;11(1):84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions